Pharmacotherapy for pulmonary sarcoidosis: A delphi consensus study  by Schutt, Amanda C. et al.
Respiratory Medicine (2010) 104, 717e723ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedPharmacotherapy for pulmonary sarcoidosis:
A delphi consensus studyAmanda C. Schutt a, Wendy M. Bullington b, Marc A. Judson c,*a Medical University of South Carolina Medical Center and College of Pharmacy, 150 Ashley Avenue, PO Box 250584,
Charleston, SC 29425, USA
b Medical University of South Carolina Medical Center, Department of Pharmacy, 150 Ashley Avenue, PO Box 250584,
Charleston, SC 29425, USA
c Medical University of South Carolina Medical Center, Department of Medicine, Division of Pulmonary and Critical Care
Medicine, 96 Jonathan Lucas Street, Box 250630, 812 CSB, Charleston, SC 29425, USA
Received 7 October 2009; accepted 20 December 2009
Available online 20 January 2010KEYWORDS
Sarcoidosis;
Corticosteroids;
TherapyAbbreviations: ICS, inhaled corticos
Association of Sarcoidosis and Other G
* Corresponding author. Tel.: þ1 (84
E-mail address: judsonma@musc.e
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2009.12.009Summary
Background: Most issues concerning pharmacotherapy of pulmonary sarcoidosis have not been
resolved in clinical trials. Theobjectivewas to survey sarcoidosis experts concerning the treatment
ofpulmonary sarcoidosis andattempt to reacha consensus by theseexperts using aDelphimethod.
Methods: A 6-item questionnaire was developed. Experts were identified at the Diffuse Lung
Disease Network at the annual CHEST meeting in October 2008. Three rounds of questionnaires
were presented to the experts. Respondent feedback and supporting literature was incorporated
into the questionnaires of subsequent rounds.
Results: Experts reached a consensus concerning the following issues: (a) corticosteroids are the
initial therapy of choice; (b) initial use of inhaled corticosteroids are not recommended; (c) meth-
otrexate was the preferred second-line drug; (d) 40 mg of daily prednisone equivalent was the
maximum dose recommended for the treatment of acute pulmonary sarcoidosis; (e) tapering to
10 mgofdailyprednisoneequivalent for chronicpulmonary sarcoidosiswasconsidereda successful
taper. The experts could not resolve the following issues: (a) the initial corticosteroid dose for the
treatment of acute pulmonary sarcoidosis; (b) the decision and timing of corticosteroid therapy in
a patient with mild, Stage 2 pulmonary sarcoidosis.
Conclusions: This Delphi study revealed that sarcoidosis experts reached a consensus concerning
several aspects of the treatment of pulmonary sarcoidosis; these could be considered as appro-
priateapproaches to therapy.Other issues concerning the therapyofpulmonary sarcoidosis remain
unresolved by experts, and are areas where further clinical research could be directed.
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10,11 TheTable 1 Characteristics of the sarcoidosis experts who
participated in the study.
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No response 4Pulmonary sarcoidosis is a systemic, granulomatous disease
with a variable clinical course.1e6 Because of this clinical
variability, treatment is not mandated in all cases. Cortico-
steroids modify the granulomatous inflammation and are
considered the medications of choice for pulmonary
sarcoidosis.4, 7e9 However, there are no clear guidelines for
initiating corticosteroid therapy, determining when cortico-
steroid therapy has failed, and for considering an alternative
medication for the treatment of pulmonary sarcoidosis.
The lack of standardization concerning the treatment of
pulmonary sarcoidosis results from inadequate clinical trials.
Most published studies have involved few subjects, used
varying corticosteroid doses or durations, used variable
endpoints, and have often not been blinded, randomized, or
controlled.9
This inadequate rigorous trial data makes consideration
of a Delphi research technique reasonable. A Delphi
method of polling an expert panel may enable a consensus
to be reached in situations where there are inadequate
data to determine an objective answer. The aim of this
study was to perform a Delphi study of sarcoidosis experts
concerning the treatment of pulmonary sarcoidosis using
rigorous Delphi study methods including iterative ques-
tioning and feedback from previous responses, and to
formulate a consensus by these experts whenever possible.
Methods
This study was approved by the Institutional Review Board
of the Medical University of South Carolina.
A modified Delphi method was used in this study in an
effort to reach a consensus among the experts. The key
aspects of Delphi studies include repeated expert ques-
tioning, anonymous responses, and feedback from respon-
dents. Multiple-choice questions were used to shorten the
time necessary to reach consensus versus proposing open-
ended questions.10,11
An initial 6-item questionnaire, with additional questions
concerning the experts’ clinical experience, was developed
for distribution. All 6 questions concerned the medical
treatment of pulmonary sarcoidosis. The survey was limited
to 6 questions to encourage a high response rate. All
respondents, except for 2, attended theDiffuse LungDisease
Network meeting at the annual American College of Chest
Physicians (CHEST) meeting in October 2008 in Philadelphia,
PA. An announcement was made during the meeting con-
cerning the study, and a hard copy of the questionnaire was
distributed. In addition, the form requested that each
participant supply a contact email address. Participants
completed the initial questionnaire at the conclusion of the
meeting and it was collected by the distributor. Two addi-
tional internationally renowned sarcoidosis experts were
recruited and completed the initial questionnaire via e-mail.
The sarcoidosis experts are listed in Appendix 1.
Subsequent questionnaires were disseminated by email to
all the experts. Feedback from respondents was considered
and incorporated into revisions of the questions. As is rec-
ommended in Delphi studies, the experts were encouraged to
supply literature, data, and rationale for their responses thatexperts were also allowed to comment on the questions in
terms of their validity, specificity, and content. The feedback
from each expert was provided to the entire group when the
next questionnaire was disseminated. Respondents had
access to the anonymous responses of all the experts from
previous questionnaire rounds. Such anonymity is essential in
Delphi studies to prevent bias by influential clinicians and to
reduce the pressure to conform to a group.10,11 The goal of
a Delphi study is to reach a consensus. At least 70% agreement
of respondents has been proposed to represent a consensus10;
therefore, this criterion was used in this study.
Three to 5 question rounds are most often performed in
Delphi studies. Three rounds were planned for this Delphi
study with the option of performing additional rounds if
necessary to reach a consensus.
Results
Characteristics of the experts
Table 1 displays the characteristics of the respondents.
Thirty-six respondents completed Round #1 of the ques-
tionnaire. Almost all (25/28, 89%) had completed training
for at least 5 years. The majority of respondents treated
more than 25 sarcoidosis patients per year (22/34, 65%) and
Table 2 Round #1 questions and responses (nZ 36).
Question #1: You determine that a patient should be
treated for pulmonary sarcoidosis. What is your initial






Other (3, 8%) other responses included: inhaled steroids,
combination of steroids and methotrexate, and depends
on severity, if early with many symptoms would use
prednisone and if later in disease would use methotrexate
or hydroxychloroquine
Question #2: For question 1, what is your initial daily dose
(if you selected corticosteroids, use prednisone- equivalent
dosing; if you selected a drug that you do not dose daily
then specify the frequency of dosing)? (nZ 36)
40 mg (10, 28%)
20 mg (9, 25%)
1 mg/kg (3, 8%)
30 mg (2, 5.5%)
20e40 mg (2, 5.5%)
30e40 mg (2, 5.5%)
0.5 mg/kg (2, 5.5%)
40 mg every other day (2, 5.5%)
0.5e1 mg/kg (1, 3%)
1.5e2 mg/kg (1, 3%)
40e60 mg (1, 3%)
Inhaled budesonide 1600mcg (1, 3%)
Question #3: A 40-year-old woman presents with mild
dyspnea and cough. Spirometry reveals a FVC 71% of
predicted, FEV1 72% of predicted. Her past medical history
is not significant. She is found to have Stage 2 pulmonary
sarcoidosis via CXR. Assume that there is essentially no
change in her spirometry or symptoms
for the foreseeable future, when do you initiate
SYSTEMIC (ORAL OR INTRAVENOUS) treatment for
pulmonary sarcoidosis? (nZ 30)
Now (11, 37%)
I would never give that patient a trial of systemic
therapy if spirometry and symptoms were essentially
unchanged (17, 57%)
In 3 months (1, 3%)
In 6 months (1, 3%)
Question #4: I would consider corticosteroid treatment
of acute pulmonary sarcoidosis a failure if the patient
did not respond after 3 months at what daily prednisone
equivalent dose? (nZ 36)
40 mg (20, 56%)
20 mg (8, 22%)
30 mg (3, 8%)
60 mg (2, 6%)
40 mg every other day (1, 3%)
0.5 mg/kg (1, 3%)




Table 2 (continued )
Question #5: I would consider corticosteroid treatment
of chronic pulmonary sarcoidosis a failure if the
maintenance daily prednisone equivalent dose could
not be tapered lower than: (nZ 36)
10 mg (15, 38%)
20 mg (10, 29%)
15 mg (5, 15%)
5 mg (3, 9%)
7.5 mg (2, 6%)
0 mg (1, 3%)
40 mg (0)
30 mg (0)
Question #6: The second-line agent that I add to
corticosteroids or replace corticosteroids with in patients
with sarcoidosis who have an inadequate response to




Indicated more than one response,including methotrexate,





Pharmacotherapy for pulmonary sarcoidosis 719had been involved in at least 1 sarcoidosis publication
(20/33, 59%). Almost half of the experts had been involved
in at least 1 clinical sarcoidosis trial (14/32, 44%). The
majority of respondents (33/36, 92%) indicated pulmonary/
critical care medicine as their subspecialty area of prac-
tice, with 3 noting their subspecialty practice as interstitial
lung disease, sarcoidosis, or transplant.
Round #1
The 6 questions and experts’ responses are shown in Table 2.
Question #1: ninety-two percent (33/36) agreed that
corticosteroids are the preferred initial therapy for
pulmonary sarcoidosis. This question was deemed to have
reached consensus and was not included in further rounds.
Question #2: the responses varied widely for the initial
daily dose of corticosteroids. No consensus was reached
concerning this question.
Question #3: the responses were divided between start-
ing systemic corticosteroids immediately (11/30, 36%), never
starting corticosteroids if spirometry and symptoms were
essentially unchanged (17/30, 57%), and waiting 3e6 months
to follow the natural course of the disease before consid-
ering therapy (2/30, 7%) for a patient with mild symptoms
and Stage 2 pulmonary sarcoidosis. Seventeen percent
(6/36) of the experts did not give a definitive answer.
Several experts desired additional information about the
patient (e.g. diffusing capacity and patient’s desire for
therapy). Two experts chose inhaled corticosteroids (ICS).
No consensus was reached concerning this question.
Question #4: experts considered corticosteroid treat-
ment of acute pulmonary sarcoidosis a failure if the patient
did not respond after 3 months of daily corticosteroid
Table 3 Round #2 questions and responses (nZ 30).
Question #1: You determine that a patient should be
treated for pulmonary sarcoidosis with oral corticosteroids.




Does not use oral corticosteroids (1, 3.5%)
Question #2: What is your initial daily dose of oral
corticosteroids for pulmonary Sarcoidosis (use prednisone
equivalent dosing)? (nZ 30)
40 mg regardless of weight (11, 37%)
20 mg regardless of weight (6, 20%)
20, 30, or 40 mg depending on weight (7, 23%)
0.5 mg/kg (3, 10%)
30 mg regardless of weight (2, 7%)
1 mg/kg (1, 3%)
Question #3: A 40-year-old woman presents with mild
dyspnea and cough. Spirometry reveals a FVC 71% of
predicted, FEV1 72% of predicted, and DLCO 70% of
predicted. Her past medical history is not significant.
She is found to have Stage 2 pulmonary sarcoidosis
via CXR. Assume that there is essentially no change in
her spirometry or symptoms for the foreseeable future
and you have discussed the pros and cons of
corticosteroids with the patient, when do you initiate
SYSTEMIC (ORAL OR INTRAVENOUS) treatment for
pulmonary sarcoidosis? (nZ 29)
I would refrain from giving that patient a trial of
systemic therapy if spirometry and symptoms were
essentially unchanged (15, 51.7%)
Now (8, 27.6%)
I would follow the patient without therapy. If after
X months, her symptoms and pulmonary function
do not improve, I would initiate corticosteroid therapy:
In 6 months (3, 10.3%)
In 3 months (1, 3.4%)
In 3e6 months (1, 3.4%)
did not indicate duration of waiting period (1, 3.4%)
Question #4: I would consider corticosteroid treatment
of acute pulmonary sarcoidosis a failure if the patient
did not respond after 3 months at what daily prednisone
equivalent dose? (nZ 30)
40 mg (23, 77%)
20 mg (4, 13%)
60 mg (2, 7%)
30 mg (1, 3%)
15 mg (0)
10 mg (0)
Question #5: I would consider corticosteroid treatment
of chronic pulmonary sarcoidosis a failure if the
maintenance daily prednisone equivalent dose could
not be tapered lower than: (nZ 30)
10 mg (20, 66.7%)
20 mg (3, 10%)
15 mg (3, 10%)
30 mg (2, 6.7%)
5 mg (2, 6.7%)
40 mg (0)
7.5 mg (0)
Table 3 (continued )
Question #6: Please rank your top 2 choices for second-line
agents that you would add to corticosteroids or replace
corticosteroids with in patients with pulmonary sarcoidosis
who have an inadequate response to corticosteroids















Mycophenolate mofetil (1, 4%)
Thalidomide (0)
Leflunomide (0)
720 A.C. Schutt et al.therapy (reported as prednisone equivalent dosing) ranging
from 15 to 60 mg. However, these data can also be inter-
preted as 94% (32/34) of experts agreed that treatment
with greater than 40 mg of daily prednisone equivalent
would not provide any additional benefit to the patient. In
this sense, a consensus was reached concerning this ques-
tion. However, the question was reposed to determine if
a more definitive dose could be established.
Question #5: similar to question #4, the corticosteroid
dose selections were wide. However, 83% (30/36) agreed
that a taper of the maintenance prednisone equivalent
dose to 10 mg daily is a successful corticosteroid taper for
chronic pulmonary sarcoidosis. In this sense, a consensus
was reached concerning this question. Nonetheless, the
question was reposed in the next round to try to determine
if a more definite response could be established.
Question #6: sixty-six percent (23/35) of experts felt
that methotrexate was the second-line agent of choice in
addition to, or to replace corticosteroids if patients had an
inadequate response to corticosteroids alone. Twelve
respondents chose azathioprine, hydroxychloroquine, or
infliximab as a second-line agent. This question did not
reach the specified criteria of 70% to reach a consensus, so
it was modified in further rounds.
Round #2
The 6 questions and experts’ responses are shown in Table 3.
Question #1: because several respondents made
comments about ICS in Round #1, this new question was
added to the questionnaire. Eighty-six percent of experts
(25/29) would not simultaneously initiate concomitant ICS
in addition to oral corticosteroids. The question reached
a consensus.
Question #2: comments to this question in the first round
included consideration of weight-based dosing regimens,
and therefore, weight-based choices were included in the
second round of this question. However, the responses did
not reach a consensus, and it was felt that further rounds
would unlikely reach a consensus.
Question #3: this question was slightly modified based on
the experts’ comments to include additional patient char-
acteristics including diffusing capacity and the patient’s
awareness of the benefits and potential risks of cortico-
steroid therapy. Again, there was a significant discordance
Pharmacotherapy for pulmonary sarcoidosis 721in the responses to this question. It was concluded that
a consensus would not be reached concerning this question.
Question #4: the actual corticosteroid dose selections
again remained wide as with the first round of this question.
However, an overwhelming majority (28/30, 93%) of experts
agreed that treatment of acute pulmonary sarcoidosis with
greater than 40 mg of prednisone daily equivalent would not
provide any additional benefit. In this sense, a consensus
was reached concerning this question.
Question #5: similar to question #4, the actual cortico-
steroid dose selections again remained wide as with the
first round of this question. However, 93% (28/30) agreed
that a taper of the maintenance prednisone equivalent
dose to 10 mg daily is a successful corticosteroid taper for
chronic pulmonary sarcoidosis. In this sense, a consensus
was reached concerning this question.
Question #6: this question was modified to instruct the
experts to rank their second and third-line agents after
corticosteroids. Pulmonary sarcoidosis was also specified as
the type of sarcoidosis to be treated for this question.
Methotrexate was selected overwhelmingly (25/30, 83%) as
the second-line drug. A consensus was therefore reached.
A consensus could not be reached concerning a third-line
drug.Round #3
The 2 questions and experts’ responses are shown in Table 4.
Questions A and B: Although question A was essentially
identical to the first part of question #6 in Round #2 which
reached consensus, it was reposed in question A so that
respondents had a separate question (question B) to
respond to their third-line drug choice. This was performed
because several experts omitted a third-line agent in Round
#2. Again, methotrexate was selected overwhelminglyTable 4 Round #3 questions and responses (nZ 32).
Question A Please indicate ONE second-line agent that you
would add to corticosteroids or replace corticosteroids with
in patients with pulmonary sarcoidosis who have an








Question B: Please indicate ONE third-line agent that you
would add to corticosteroids or replace corticosteroids with
in patients with pulmonary sarcoidosis who have an






Mycophenolate mofetil (1, 3%)
Thalidomide (0)
Leflunomide (0)(25/32, 78%) as the second-line drug and a consensus was
reached. There was wide variation in the third-line agent
choice so that a consensus could not be reached.
Consistency of responses
Consistency of answers was assessed as the percent of
respondents who changed their answers between Rounds #1
and #2, as shown in Table 5. Although there was significant
inconsistency in the responses, the inconsistencies to
questions #4, #5, and #6, did not affect the consensuses
reached.
The relationship between experience and
responses
In comparing experts who indicated they treated at least
100 patients per year with sarcoidosis (nZ 9) to those who
treated less than 100 patients per year (nZ 27), there were
no differences concerning any of the consensuses that were
reached (Table 6).
Discussion
The treatment of pulmonary sarcoidosis is not standard-
ized. This is the result of inadequate clinical trials that are
often not placebo-controlled or randomized, have had
variable clinical endpoints, and have included a small
number of subjects.9 In such cases where there are insuf-
ficient evidence-based data to determine optimal medical
therapy, the Delphi technique has been used as a surrogate
approach to develop a consensus.
We believe that this Delphi study involved respondents
that were pulmonary sarcoidosis experts. More than two-
thirds treated greater than 25 sarcoidosis patients per year,
nearly half had been involved in at least 1 clinical
sarcoidosis trial, and almost two-thirds had been involved
in at least one sarcoidosis publication. Furthermore, there
were no major differences in the responses of experts who
treated at least 100 sarcoidosis patients per year compared
to those that treated less than 100 patients per year. This
suggests that even though there was significant variation in
the degree of clinical sarcoidosis care and research per-
formed by the experts, they were consistent in terms of
their opinions.
The response rate in this study ranged from 83 to 100% in
all 3 rounds of the questionnaire. Several treatment ques-
tions were not posed in this study in an effort to improveTable 5 Consistency of responses.
Percentage of experts
that changed responses
between Rounds 1 and 2
Percent of experts
whose response changed
and moved out of consensus
Question # 2 25 N/A
Question # 3 15 N/A
Question # 4 30 3
Question # 5 57 3
Question # 6 22 6
N/A: not applicable.
Table 6 Relationship between experience and responses.a
Question Consensus Experts caring for 100
sarcoidosis patients per year
who reached consensus, n (%)
Experts caring for <100
sarcoidosis patients per year
who reached consensus, n (%)
Round 1, Question 1 Corticosteroids are the drug of
choice
7/9 (78) 24/25 (96)
Round 1, Question 4 Acute pulmonary sarcoidosis should
not be treated with more than
40 mg/day of daily prednisone
equivalent.
7/9 (78) 22/25 (88)
Round 1, Question 5 A successful taper is to 10 mg/day
of daily prednisone equivalent.
8/9 (89) 22/25 (88)
Round 2, Question 1b ICS is not recommended for initial
therapy.
6/8 (75) 17/19 (89)
Round 2, Question 4c Acute pulmonary sarcoidosis should
not be treated with more than
40 mg/day of daily prednisone
equivalent.
7/8 (88) 19/20 (95)
Round 2, Question 5c A successful taper is to 10 mg/day
of daily prednisone equivalent.
8/8 (100) 18/20 (90)
Round 2, Question 6c Methotrexate is 2nd line therapy. 7/8 (88) 17/20 (85)
Round 3, Question Ad Methotrexate is 2nd line therapy. 8/8 (100) 16/21 (76)
ICS: inhaled corticosteroids.
a 2 experts did not indicate the number of patients with sarcoidosis they treated per year; 9 experts cared for 100 sarcoidosis
patients per year; 25 experts cared for <100 sarcoidosis patients per year.
b 7 experts did not respond.
c 6 experts did not respond.
d 5 experts did not respond.
722 A.C. Schutt et al.response rates. Questions were limited to only a number of
important treatment-related issues.
This study was able to reach a consensus on several
issues concerning the treatment of pulmonary sarcoidosis.
First, oral corticosteroids are the recommended initial
treatment for pulmonary sarcoidosis. Second, it is not
routinely recommended to initiate concomitant ICS along
with oral corticosteroids at the time of initial treatment.
Third, a consensus was reached that no additional benefit
would be achieved by treating acute pulmonary sarcoidosis
with more than 40 mg of prednisone daily equivalent.
Fourth, a consensus was reached that a taper of cortico-
steroids to a maintenance dose of 10 mg of prednisone daily
equivalent was a successful taper for the treatment of
chronic pulmonary sarcoidosis. Finally, methotrexate was
the consensus preferred agent for corticosteroid sparing
effects or replacement of corticosteroids.
Several questions posed to the sarcoidosis experts did
not reach consensus. We would classify these questions as
‘‘controversial’’ and believe that they are important areas
for future clinical research. First, the initial treatment
dose of corticosteroids for new onset pulmonary sarcoid-
osis was not resolved. The American Thoracic Society/
European Respiratory Society/World Association of
Sarcoidosis and Other Granulomatous (ATS/ERS/WASOG)
Disorders Consensus Statement on Sarcoidosis recommends
20e40 mg of daily prednisone equivalent as the initial dose
for the treatment of sarcoidosis.12 Using this wide dose
range, 75e87% (27/36 in Round #1, 26/30 in Round #2) of
the experts agreed, and in this sense a consensus was
reached.Second, the decision to treat or to observe a patient with
mild pulmonary sarcoidosis as judged by symptoms, pulmo-
nary function, and chest radiograph was uncertain among
experts. As several studies have shown that corticosteroid
therapy improves the short term but not long term outcome
of pulmonary sarcoidosis,13e16 some have advocated
observing mild cases of pulmonary sarcoidosis for a period of
time.4,6,17 The experts could not resolve this issue.
Interestingly, there was an inconsistency between the
rounds concerning the experts’ responses that involved
corticosteroid dosing. This suggests that even sarcoidosis
experts do not have a consistent dose of corticosteroids
that they use for the treatment of pulmonary sarcoidosis. It
is possible that several experts changed their answers
because of feedback to questions from the group. However,
it is important to note that this variation was not great
enough to alter the consensuses that were reached.
This studyhas severalpotential limitations.First, theuseof
multiple-choice questions can potentially limit responses or
induce bias.11 However, this study encouraged the experts to
include a text comment on all questions and allowed for the
opportunity to add to the existing responses. These comments
from the experts were often incorporated into further rounds
of the questionnaire. Second, there was not a complete
response of all the experts or to all of the questions. However,
the response rate was relatively high with 83e100% of the
experts responding to the 3 rounds and 81 to 100% of all
questions receiving responses. Third, not all of the responders
may have been pulmonary sarcoidosis experts. Nevertheless,
we demonstrated (Table 6) that the entire group came to
a similar consensus as the experts with the greatest clinical
Imre Noth; Maria L. Padilla; Herbert Patrick; Linda
Perkins.
Marilynn Prince-Fiocco; Ganesh Raghu; Hina Sahi; O.
P. Sharma.
Hidenobu Shigemitsu; Charlie Strange; Mary E. Strek;
Mark Wencel.
Timothy PM Whelan; Eric S. White.
Pharmacotherapy for pulmonary sarcoidosis 723experience.Finally, themajorityof theexpertspractice in the
United States. It is possible that these resultsmay not apply to
some international populations, as the phenotypic expression
of sarcoidosis varies throughout the world.
In conclusion, this Delphi study revealed several aspects
of the treatment of pulmonary sarcoidosis which reached
a consensus opinion by sarcoidosis experts; these could be
considered as appropriate approaches to therapy given the
lack of evidenced-based data. Other questions concerning
the therapy of pulmonary sarcoidosis remain unresolved by
experts, and are areas where further clinical research could
be directed.
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